1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
    Meeting Abstract

    Pant, S.; Ducreux, M.; Harding, J. J.; Javle, M. M.; Oh, D. Y.; Wasan, H. S.; Fortenberry, A.; Josephson, N. C.; Mwatha, A.; Wang, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations
    Meeting Abstract

    Pant, S.; Tabernero, J.; Massard, C.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D. R.; Garcia-Corbacho, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery
    Meeting Abstract

    Ku, G. Y.; Winter, K. A.; Williams, T. M.; Adusumilli, P. S.; Nishimura, M.; Yock, A.; Ilson, D. H.; Hong, T. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Sihag, S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer
    Meeting Abstract

    Lumish, M. A.; Sabwa, S.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; Joshi, S. S.; Gu, P.; Strong, V. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas
    Meeting Abstract

    Katz, M. H. G.; Shi, Q.; Meyers, J. P.; Herman, J. M.; Choung, M.; Wolpin, B. M.; Ahmad, S.; de Wilton Marsh, R.; Schwartz, L. H.; Behr, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Global BRAF testing practices in metastatic colorectal cancer
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Ciardiello, F.; Desai, J.; Kim, T. W.; Maughan, T.; Van Cutsem, E.; Wasan, H. S.; Yaeger, R.; Yoshino, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3
    Meeting Abstract

    Klempner, S. J.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V. T.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shah, M. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
    Meeting Abstract

    Janjigian, Y. Y.; Viglianti, N.; Liu, F.; Mendoza-Naranjo, A.; Croydon, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations
    Meeting Abstract

    Javle, M. M.; Kelley, R. K.; Springfeld, C.; Abou-Alfa, G. K.; Macarulla, T.; Tanasanvimon, S.; Goyal, L.; Borbath, I.; Bitzer, M.; Yong, W. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save